Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous peripheral blood CD34+ cells
- Development stage
- Unknown
- Lead developer
- Atsuhiko Kawamoto
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intramuscular
01
Overview
Autologous peripheral blood CD34+ cells are a cell therapy product composed of hematopoietic stem and progenitor cells (HSPCs) harvested from a patient's own blood, typically following mobilization with granulocyte colony-stimulating factor (G-CSF). These cells are enriched for the CD34 surface marker and are utilized for their potent pro-angiogenic and vasculogenic properties. When administered via intramuscular injection into ischemic tissues, these cells promote the formation of new blood vessels by differentiating into endothelial cells and secreting paracrine factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF). This therapeutic approach is primarily developed for patients with chronic critical limb ischemia (CLI) and peripheral artery disease (PAD) who are not candidates for standard surgical or endovascular revascularization.
- Other names
- autologous CD34+ cellsperipheral blood CD34+ cellsautologous CD34+ hematopoietic stem cells
Beyond the preview
Go deeper on autologous peripheral blood CD34+ cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous peripheral blood CD34+ cells.